论文部分内容阅读
Venetoclax是AbbV ie艾伯维公司和罗氏Genentech基因泰克公司合作研发的一个选择性的Bcl-2抑制剂,用于治疗慢性淋巴细胞白血病,非霍奇金淋巴瘤,小淋巴细胞淋巴瘤,弥漫性大B细胞淋巴瘤,多发性骨髓瘤等。最早于2011年进入临床,迄今为止共开展25项临床试验。复发或难治性慢性淋巴细胞白血病已进入III期临床研究。venetoclax单药治疗慢性淋巴细胞白血病的总
Venetoclax, a selective inhibitor of Bcl-2 developed by AbbV, in collaboration with Genentech Genentech, is used to treat chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, small lymphocytic lymphomas, diffuse Large B cell lymphoma, multiple myeloma and so on. As early as 2011 into clinical, so far carried out a total of 25 clinical trials. Relapsed or refractory chronic lymphocytic leukemia has entered Phase III clinical studies. Total venetoclax monotherapy for chronic lymphocytic leukemia